News Image

Delving into NASDAQ:ALKS's Growth Prospects.

By Mill Chart

Last update: Dec 26, 2023

Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if ALKERMES PLC (NASDAQ:ALKS) is suited for growth investing. Investors should of course do their own research, but we spotted ALKERMES PLC showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.

What matters for growth investors.

  • The Return on Equity(ROE) of ALKERMES PLC is 15.85%, which is a strong number. This indicates the company's ability to generate favorable returns for shareholders and reflects its effective management of resources.
  • ALKERMES PLC has a strong history of beating EPS estimates in the last 4 quarters, signaling its ability to consistently exceed market expectations. This indicates the company's strong financial performance and its potential for creating shareholder value.
  • With impressive 1-year revenue growth of 40.56%, ALKERMES PLC showcases its ability to generate increased sales and revenue. This growth highlights the company's strong customer demand and its effective business strategies.
  • ALKERMES PLC has demonstrated strong q2q revenue growth of 50.91%, suggesting a favorable trend in the company's financials and indicating the potential for continued expansion.
  • The operating margin of ALKERMES PLC has seen steady growth over the past year, signaling improved profitability. This trend indicates the company's effective cost management and its ability to generate higher returns.
  • ALKERMES PLC has experienced notable growth in its free cash flow (FCF) over the past year, signaling improved cash generation and strong financial performance. This growth suggests the company's ability to generate excess cash for reinvestment or shareholder returns.
  • ALKERMES PLC has demonstrated consistent growth in its earnings per share (EPS) from one quarter to another (Q2Q), with a 3.0K% increase. This indicates improving financial performance and the company's effective management of its operations.
  • The average next Quarter EPS Estimate by analysts was adjusted by 7.33%, reflecting the evolving market expectations for the company's EPS growth.
  • The recent financial report of ALKERMES PLC demonstrates a 3.0K% increase in quarterly earnings compared to the previous quarter. This growth indicates positive momentum in the company's financials and suggests a promising upward trend
  • The earnings per share (EPS) growth of ALKERMES PLC are accelerating: the current Q2Q growth of 3.0K% is above the previous year Q2Q growth of -85.71%. Earnings momentum and acceleration are key for high growth systems.

Fundamental Analysis Observations

ChartMill assigns a Fundamental Rating to every stock. This score, ranging from 0 to 10, is updated daily and is determined by evaluating multiple fundamental indicators and properties.

Taking everything into account, ALKS scores 6 out of 10 in our fundamental rating. ALKS was compared to 605 industry peers in the Biotechnology industry. Both the profitability and the financial health of ALKS get a neutral evaluation. Nothing too spectacular is happening here. ALKS is evaluated to be cheap and growing strongly. This does not happen too often! This makes ALKS very considerable for value and growth investing!

Check the latest full fundamental report of ALKS for a complete fundamental analysis.

Our Lois Navellier screen will find you more ideas suited for growth investing.

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

ALKERMES PLC

NASDAQ:ALKS (4/23/2024, 3:15:00 PM)

After market: 24.26 0 (0%)

24.26

+0.19 (+0.79%)

ALKS News

News Image4 days ago - Market News VideoFirst Week of June 21st Options Trading For Alkermes (ALKS)
News Image6 days ago - Alkermes plcAlkermes to Report First Quarter Financial Results on May 1, 2024

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to...

News Image6 days ago - ChartmillInvestors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents.

Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag.

News Image12 days ago - Market News VideoOversold Conditions For Alkermes (ALKS)
News Image13 days ago - ChartmillExploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS).

ALKERMES PLC (NASDAQ:ALKS) may be suited for growth investing, we'll explore why in this article.

News Image15 days ago - Alkermes plcAlkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International...

News Imagea month ago - Market News VideoNoteworthy Tuesday Option Activity: ALKS, DKNG, VRT
News Imagea month ago - Market News VideoFirst Week of ALKS November 15th Options Trading
News Image2 months ago - Alkermes plcAlkermes Announces Appointment of Nancy S. Lurker to Board of Directors

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors...

News Image2 months ago - Investor's Business DailyAmicus Therapeutics Stock Sees RS Rating Improve To 74

In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.

News Image2 months ago - Investor's Business DailyBeam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat

Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81.

News Image2 months ago - Investor's Business DailyAgios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark

Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84.

ALKS Links
Follow us for more